Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
| ▸ | CCKBR | P32239 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10523388 | 0.84 | FNTA (0.42) | GNPATFNTAFNTBPGGT1BBACE1 | |
| SCHEMBL10523396 | 0.84 | FNTA (0.42) | GNPATFNTAFNTBPGGT1BBACE1 | |
| SCHEMBL30051202 | 0.84 | FNTA (0.45) | FNTAFNTBPGGT1BLTA4HLMNA | |
| SCHEMBL31412197 | 0.83 | FNTA (0.41) | FNTAFNTBPGGT1BBACE1CCKBR | |
| SCHEMBL11662923 | 0.83 | FNTA (0.49) | FNTAFNTBPGGT1BLMNA | |
| SCHEMBL11662915 | 0.83 | FNTA (0.49) | FNTAFNTBPGGT1BLMNA | |
| SCHEMBL21261601 | 0.82 | LTA4H (0.43) | FNTAFNTBPGGT1BLTA4HBACE1 | |
| SCHEMBL21261602 | 0.82 | LTA4H (0.43) | FNTAFNTBPGGT1BLTA4HBACE1 | |
| SCHEMBL7987401 | 0.82 | FNTA (0.48) | FNTAFNTBPGGT1BLMNA | |
| SCHEMBL7987408 | 0.82 | FNTA (0.48) | FNTAFNTBPGGT1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | GNPAT 1529/4885FNTA 1639/4885FNTB 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.